# Pharmabiotics2023 Conference & Partnering

21-22 March Hosted by Spri

## **Conference Programme**

## Day 1 - 21 March 2023

08:15-09:00	Welcome Coffee & Registrations		
09:00-09:05		<b>Conference Opening &amp; Welcome Address Day 1</b> <b>Sandrine Claus</b> <i>President</i> , Pharmabiotic Research Institute	
09:05-10:20		Fundamental Science Session	Chaired by Bruno Pot
09:05-09:30		<b>The Tumor Mycobiome</b> <b>Ravid Straussman</b> <i>Principal Investigator,</i> Weizmann Institute of Science	
09:30-09:55		Lung Microbiome-based Diagnosis and Therapeutic in C Disease Genevieve Hery-Arnaud Professor of Bacteriology, University of Brest	Chronic Pulmonary
09:55-10:20		The Role of Gut Microbiota in Cancer Immunotherapy Carolina Alves Costa Silva PhD Student, Gustave Roussy	
	Keynote	e Presentation	
10:20-10:50		A Regulatory Science Journey to the First FDA Approved Drug Ken Blount VP Microbiome Research, Ferring Pharmaceuticals	d Microbiome-based
10:50-11:30	Coffee Break		
11:30-12:45		Discovery & Preclinical c	haired by François Leulier 🗰
11:30-11:55		Developing a Rational Phage Therapy Treatment Laurent Debarbieux Research Director, Institut Pasteur	
11:55-12:20		Disentangling the Microbiome of Inflammatory Bowel D Machine Learning Marcus Claesson Associate Professor, Univeristy College Cork	Disease and the Role of
12:20-12:45		Challenges, Efforts and Initiatives to Promote Microbion Discovery in Japan Jun Terauchi Steering Committee Chair, Japan Microbiome Consortium CSO, Metagen Therapeutics Inc.	ne-based Drug
12:45-12:55	Lunch	Lyon, a Dynamic Place for Microbiome R&D: the "Cynbic Florent Gerbaud Lead Advisor, Healthcare and Life Sciences, ADERLY - Inves	

14:00-16:00	Keynote Session: From Concept to Consortium Chaired by Tomas de Wouters		
14:00-14:20	Contrasting Data-Driven and Microbiology Driven Approaches for Microbiome Hypothesis Creation		
	Patricia Lepage Research director, Team leader, INRAE		
14:20-14:40	Engineering a Complex Synthetic Microbial Community for Modulation of Bile Acids		
14:40-15:00	<ul> <li>Alice Cheng Clinical Assistant Professor, Stanford University</li> <li>Lessons From Synthetic Human Gut Communities</li> </ul>		
	Karoline Faust Associate Professor, KU Leuven		
15:00-15:20	From Mice to Men - Which Models Should be Used for Pre-Clinical Validation of Microbiome Therapeutics?		
	Bärbel Stecher Professor, LMU Munich		
15:20-15:40	Engineering Defined Bacterial Consortia for Therapeutics Based on Trophic Interactions		
	Gabriel E. Leventhal CSO, PharmaBiome AG		
15:40-16:00	BMC128- A Rationally Designed LBP Consortium's Journey to the Clinic		
	Shiri Meshner VP R&D, Biomica Ltd.		
16:00-16:30	Panel Discussion: From Concept to Consortium		
	Patricia Lepage Research Director, Team Leader, INRAE Tomas de Wouters Co-founder/CEO, PharmaBiome AG Alice Cheng Clinical Assistant Professor, Stanford University Bärbel Stecher Professor, LMU Munich Noora Ottman Head of Drug Substance Development, Bacthera		
16:30-17:00	Coffee Break		
17:00-18:00	SoHO Revision and its potential impact(s) on microbiome-based medicinal products		
17:00-17:25	Chaired by Jean-Paul Pirnay		
_,	Stefaan van der Spiegel Team Leader - Substances of Human Origin, European Commission		
17:25-17:50	EDQM Standards in the SoHO Field		
	Mirela Bušić Head of SoHO Standards Section, EDQM (CoE)		
17:50-18:30	Panel Discussion: SoHO Revision and its Potential Impact(s) on Microbiome-Based Medicinal Products Overview by Céline Druart		
	Sarah Lebeer Professor, University of Antwerp Randi Rich Head Of Operations, Executive Manager & Co-founder, Freya Biosciences Bruno Pot Science Director, Yakult Europe Arnaud Beurdeley Senior Regulatory Consultant/Senior Regulatory Consultant, Voisin Consulting Life Sciences (VCLS) Jean-Paul Pirnay Head of the Laboratory for Molecular and Cellular Technology (LabMCT),		
	Queen Astrid Military Hospital		


### Day 2 - 22 March 2023

08:15-08:55	Welcome Coffee & Registrations		
08:55-09:00		Conference Opening & Welcome Address Day 2 Sandrine Claus President, Pharmabiotic Research Institute	
09:00-10:00	Ŷ	Market Chaired by Georges Rawadi	
09:00-09:20		Microbiome Drug Development: What Does (Seem) to Work and What Does Not? Luis Gosálbez Managing Director, Sandwalk Bioventures	
09:20-09:40		A Future Roadmap for Microbiome-Based Therapeutics and Well-Being Investment: Perspective and Strategy Chiaki Tsuboi Director, Corundum Systems Biology	
09:40-10:00		<b>Considerations for Spinning Out: Microbiome Technology Transfer</b> <b>Hervé Ansanay</b> <i>Biotech Alliance Manager in the Industrial Partnerships Department,</i> Réseau SATT (SATT Network)	
10:00-10:30	Panel Di	iscussion: Translational Microbiome	
	Georges Rawadi Chief Biotech Studio, eureKARE/Board Member, Apmonia and Alia Therapeutics Hervé Ansanay Biotech Alliance Manager, Réseau SATT (SATT Network) Heloise Breton Senior Product Manager, Microbiome Devices and Services, DNA Genotek Alex van Belkum CSO, BaseClear Nigel Titford CEO, BioGaia Pharma AB Nick Mazzucca Director of Business Development, Arranta Bio		

#### **Coffee Break** 10:30-11:00 **First In-Human Trials** 11:00-12:40 Chaired by Massimo Marzorati 11:00-11:25 Gut Microbiota in Parkinson's Disease – From the Basics to the Clinic Filip Scheperjans Adjunct Professor of Neurology, Helsinki University Hospital/CEO, NeuroBiome Ltd. 11:25-11:50 Exploration of a Live Biotherapeutic Product With lactobacilli Against SARS-CoV-2 and Related Viruses Sarah Lebeer Research Professor, University of Antwerp 11:50-12:15 Pioneering a New Class of Microbial Immunotherapies for Women's Health Randi Rich Head Of Operations, Executive Manager & Co-founder, Freya Biosciences Elleke Bosma Director Microbiome Research, Freya Biosciences 12:15-12:40 Bloom Science and Biose Industrie - A Biotech and CDMOs Journey into the Clinic Christopher Reyes CEO, Co-founder, Director, Bloom Science Claire Derlot Head of Programs, Biose Industrie

### Late Stage Clinical Trials





Co-Founder and COO, CC Biotech Ltd.



**Closing Address and Conference Close** Sandrine Claus President, Pharmabiotic Research Institute